Endocrine Abstracts

UK National Acromegaly Register collects data on real-life clinical practice in 34 centres. We analysed all GH and IGF1 data to assess adequacy of control on medical treatment (Rx) with somatostatin analogs (SMS) and dopamine agonists (DA).Methods: All GH records (basal, profile or GTT) in database were correlated with IGF1, Rx, surgery (TSS) and radiotherapy (RT), then processed to derive summary data for each patient and each course of Rx. GH considere...

Objectives: To assess bone mineral density (BMD) and body composition in adults with congenital adrenal hyperplasia (CAH).Setting: Endocrine clinics in seventeen centres throughout the UK participating in CaHASE, a Society for Endocrinology project.Study design and subjects: Cross-sectional survey of 203 adults with CAH (65 men, 138 women: median age 33 (range 18–70) years). Hundred and sixty six patients were classified as cl...

Congenital adrenal hyperplasia (CAH) represents the most common inborn metabolic error and is associated with significant morbidity and mortality. There is a paucity of clinical data in adult patients, a lack addressed by congenital adrenal hyperplasia adult study executive (CaHASE), a multicentre cross-sectional study of the health status of adults with CAH that recruited 203 patients from 17 centres (54% of patients contacted). Psychometric evaluation was assessed by validat...

CaHASE is a multicentre cross-sectional study of the health status of adults with congenital adrenal hyperplasia (CAH). Although fertility is considered to be reduced in both sexes, few published series report the proportion that has actively sought pregnancy. About 203 patients were recruited from 17 centres. Four patients (3, 11-hydroxylase, 1 HSD3B2 deficient) were excluded from analysis. Demographics are shown in Table 1.<table boarder="1" cellpadding="3" cellspacing="...

We have previously reported the following metabolic abnormalities were common in 203 adult patients with CAH: obesity (41%), hypercholesterolemia (46%), insulin resistance (29%), osteopenia (40%) and osteoporosis (7%) (Arlt et al. JCEM 2010 95 5110–21). The CAH patients were taking different glucocorticoid therapies at various doses (n=196): hydrocortisone (n=25 M, 26 W), prednisolone (n=21M,67W), dexamethasone (n=15M,22W) or comb...

Background: No treatment guidelines exist for CAH adults. To address this we have undertaken a cross-sectional analysis of health status.Patients and methods: Three hundred and eighty patients from 17 tertiary centres were contacted: 203 (53%) consented (138 f, 65 m, median age 34 (range 18–69) years). One hundred and sixty-five had classic and 34 non-classic CAH. The UK prevalence is 3591 adults >18 years therefore the capture rate was 5.7%. Re...